Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides

Therapeutic Delivery

Volumn 2, Issue 1, 2011, Pages 71-82

  Lindberg, Staffan ^a   Copolovici, Dana M ^b   Langel, Ülo ^a,b  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; CELL PENETRATING PEPTIDE; CHLORAMBUCIL; CIDOFOVIR; DOXORUBICIN; FOSCARNET; HYBRID PROTEIN; OCTREOTIDE; OLIGOMER; PENETRATIN; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; PRO 051; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

CANCER THERAPY; CELL SPECIFICITY; DRUG CONJUGATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENDOSOME; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENE VECTOR; GLIOBLASTOMA; HUMAN; INTRACELLULAR TRANSPORT; MUSCULAR DYSTROPHY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

EID: 79954490100     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.78     Document Type: Review

References (102)

1. Mcmenamin MM, Wood MJ. Progress and prospects: immunobiology of gene therapy for neurodegenerative disease: prospects and risks. Gene Ther. 17(4), 448-458 (2010).
2. Campos SK, Barry MA. Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7(3), 189-204 (2007). (Pubitemid 46902201)
3. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz.) 58(2), 107-119 (2010).
4. Izsvak Z, Ivics Z. Sleeping beauty transposition. Biology and applications for molecular therapy. Mol. Ther. 9(2), 147-156 (2004). (Pubitemid 38256540)
5. Stein U, Walther W, Stege A, Kaszubiak A, Fichtner I, Lage H. Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol. Ther. 16(1), 178-186 (2008).
6. Sakai M, Nishikawa M, Thanaketpaisarn O, Yamashita F, Hashida M. Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Ther. 12(7), 607-616 (2005). (Pubitemid 40468108)
7. Sheyn D, Kimelman-Bleich N, Pelled G, Zilberman Y, Gazit D, Gazit Z. Ultrasound-based nonviral gene delivery induces bone formation in vivo. Gene Ther. 15(4), 257-266 (2008). (Pubitemid 351223462)
8. Suda T, Liu D. Hydrodynamic gene delivery. Its principles and applications. Mol. Ther. 15(12), 2063-2069 (2007). (Pubitemid 350148920)
9. Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv. Drug Deliv. Rev. 57(5), 733-753 (2005). (Pubitemid 40332600)
10. Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol. Toxicol. 26(1), 69-81 (2010).
11. Tros DE, Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 40(3), 159-170 (2010).
12. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery. Biotechnol. J. 4(11), 1559-1572 (2009).
13. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269(104), 44-50 (1994).
14. Vivés E, Brodin P, Lebleu B. A truncated HIV-1 tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272(25), 16010-16017 (1997). (Pubitemid 27265584)
15. Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration by transportan. FASEB J. 12(1), 67-77 (1998). (Pubitemid 28060272)
16. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 97(24), 13003-13008 (2000).
17. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278(1), 585-590 (2003). (Pubitemid 36043612)
18. Lundberg M, Johansson M. Is vp22 nuclear homing an artifact? Nat. Biotechnol. 19(8), 713-714 (2001).
19. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126(31), 9506-9507 (2004). (Pubitemid 39031015)
20. Fischer R, Fotin-Mleczek M, Hufnagel H, Brock R. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem. 6(12), 2126-2142 (2005).
21. Murriel Cl, Dowdy SF. Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin. Drug Deliv. 3(6), 739-746 (2006). (Pubitemid 44781846)
22. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol. Ther. 10(6), 1011-1022 (2004). (Pubitemid 39625245)
23. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated tat peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280(15), 15300-15306 (2005). (Pubitemid 40562886)
24. Vercauteren D, Vandenbroucke Re, Jones AT, et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol. Ther. 18(3), 561-569 (2010).
25. El-Andaloussi S, Holm T, Langel U. Cell-penetrating peptides: mechanisms and applications. Curr. Pharm. Des. 11(28), 3597-3611 (2005). (Pubitemid 41630987)
26. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta. 1786(2), 126-138 (2008).
27. Gump JM, June RK, Dowdy SF. Revised role of glycosaminoglycans in tat protein transduction domain-mediated cellular transduction. J. Biol. Chem. 285(2), 1500-1507 (2010).
28. Nakase I, Tadokoro A, Kawabata N, et al (Pubitemid 46105438)
29. Lundin P, Johansson H, Guterstam P, et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug. Chem. 19(12), 2535-2542 (2008).
30. Letoha T, Keller-Pinter A, Kusz E, et al. Cell-penetrating peptide exploited syndecans. Biochim. Biophys. Acta 1798(12), 2258-2265 (2010).
31. Raagel H, Saalik P, Pooga M. Peptide-mediated protein delivery-which pathways are penetrable? Biochim. Biophys. Acta 1798(12), 2240-2248 (2010).
32. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873-2896 (2009).
33. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J. Control. Release 110(3), 595-604 (2006). (Pubitemid 43163449)
34. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. 124(1), 12-25 (2006). (Pubitemid 43816129)
35. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 457(7228), 426-433 (2009).
36. Soifer HS, Rossi JJ, Saetrom P. microRNAs in disease and potential therapeutic applications. Mol. Ther. 15(12), 2070-2079 (2007). (Pubitemid 350148921)
37. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70(14), 5923-5930 (2010).
38. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18(1), 181-187 (2010).
39. Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 133(Pt 4), 957-972 (2010).
40. Veedu Rn, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem. Biodivers. 7(3), 536-542 (2010).
41. Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH. Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA 16(1 118-130 (2010).
42. Hatamoto M, Ohashi A, Imachi H. Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl. Microbiol. Biotechnol. 86(2), 397-402 (2010).
43. Moulton JD, Jiang S. Gene knockdowns in adult animals: PPMOS and vivo-morpholinos. Molecules 14(3), 1304-1323 (2009).
44. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27(6), 567-571 (2009).
45. Michiue H, Eguchi A, Scadeng M, Dowdy SF. Induction of in vivo synthetic lethal rnai responses to treat glioblastoma. Cancer Biol. Ther. 8(23), 2306-2313 (2009).
46. Ciftci K, Levy RJ. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int. J. Pharm. 218(1-2), 81-92 (2001). (Pubitemid 32406159)
47. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-AHX-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release 116(3), 304-313 (2006). (Pubitemid 44827406)
48. Shiraishi T, Pankratova S, Nielsen PE. Calcium ions effectively enhance the effect of antisense peptide nucleic acids conjugated to cationic Tat and oligoarginine peptides. Chem. Biol. 12(8), 923-929 (2005). (Pubitemid 41206806)
49. Wadia Js, Stan Rv, Dowdy Sf. Transducible Tat-HA fusogenic peptide enhances escape of tat-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10(3), 310-315 (2004).
50. Choi SW, Lee SH, Mok H, Park TG. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm peg conjugate of siRNA and cell-penetrating peptide with crosslinked fusogenic peptide. Biotechnol. Prog. 26(1), 57-63 (2010).
51. Kobayashi S, Nakase I, Kawabata N, et al. Cytosolic targeting of macromolecules using a pH-dependent fusogenic peptide in combination with cationic liposomes. Bioconjug. Chem. 20(5), 953-959 (2009).
52. Oliveira S, Van Rooy I, Kranenburg O, Storm G, Schiffelers RM. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int. J. Pharm. 331(2), 211-214 (2007). (Pubitemid 46216677)
53. Min SH, Kim DM, Kim MN, et al. Gene delivery using a derivative of the protein transduction domain peptide, K-ANTP. Biomaterials 31(7), 1858-1864 (2010).
54. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21(11), 2664-2671 (2007). (Pubitemid 47372734)
55. Lo Sl, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 29(15), 2408-2414 (2008).
56. Alexis F, Lo S-L, Wang S. Covalent attachment of low molecular weight poly(ethylene imine) improves Tat peptide mediated gene delivery. Adv. Mater. 18(16), 2174-2178 (2006). (Pubitemid 44325314)
57. Myrberg H, Zhang L, Mae M, Langel U. Design of a tumor-homing cell-penetrating peptide. Bioconjug. Chem. 19(1), 70-75 (2008). (Pubitemid 351213837)
58. Kim SS, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol. Ther. 18(5), 993-1001 (2010).
59. Olson Es, Aguilera Ta, Jiang T, et al. In vivo characterization of activatable cell-penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb) 1(5-6), 382-393 (2009).
60. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell-penetrating peptides is superior to that of cell-penetrating peptides. Integr. Biol. (Camb.) 1(5-6), 371-381 (2009).
61. Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J. Control. Release 98(2), 317-323 (2004). (Pubitemid 38950740)
62. Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable peg-lipid. Gene Ther. 14(1), 68-77 (2007). (Pubitemid 44942867)
63. Yang H, Liu S, Cai H, et al. Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J. Biol. Chem. 285(33), 25666-25676 (2010).
64. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2(2), E36 (2004).
65. Araki D, Takayama K, Inoue M, et al. Cell-penetrating d-isomer peptides of p53 C-terminus: long-term inhibitory effect on the growth of bladder cancer. Urology 75(4), 813-819 (2010).
66. Xie W, Liu J, Qiu M, Yuan J, Xu A. Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs. J. Pept. Sci. 16(2), 105-109 (2010).
67. Jiang T, Olson Es, Nguyen Qt, Roy M, Jennings Pa, Tsien Ry. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA 101(51), 17867-17872 (2004). (Pubitemid 40051978)
68. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell-penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. USA 107(9), 4311-4316 (2010).
69. Aroui S, Brahim S, Waard Md, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem. Biophys. Res. Commun. 391(1), 419-425 (2010).
70. Aroui S, Brahim S, De Waard M, Breard J, Kenani A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared with unconjugated doxorubicin in the human breast cancer cell line MDA-Mb 231. Cancer Lett. 285(1), 28-38 (2009).
71. Delcroix M, Riley LW. Cell-penetrating peptides for antiviral drug development. Pharmaceuticals 3(3), 448-470 (2010).
72. Stone JK, Rijnbrand R, Stein DA, et al. A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus. Antimicrob. Agents Chemother. 52(6), 1970-1981 (2008). (Pubitemid 351758532)
73. Yuan J, Stein Da, Lim T, et al. Inhibition of coxsackievirus b3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J. Virol. 80(23), 11510-11519 (2006). (Pubitemid 44788866)
74. Stein DA. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr. Pharm. Des. 14(25), 2619-2634 (2008).
75. Kinney RM, Huang CY, Rose BC, et al. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. J. Virol. 79(8), 5116-5128 (2005). (Pubitemid 40464261)
76. Holden KL, Stein DA, Pierson TC, et al. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology 344(2), 439-452 (2006). (Pubitemid 43049631)
77. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79(8), 4599-4609 (2005). (Pubitemid 40464211)
78. Deas TS, Bennett CJ, Jones SA, et al. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51(7), 2470-2482 (2007). (Pubitemid 47047326)
79. Paessler S, Rijnbrand R, Stein Da, et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 376(2), 357-370 (2008).
80. Van Den Born E, Stein DA, Iversen PL, Snijder EJ. Antiviral activity of morpholino oligomers designed to block various aspects of equine arteritis virus amplification in cell culture. J. Gen. Virol. 86(Pt 11), 3081-3090 (2005). (Pubitemid 41555574)
81. Lai SH, Stein DA, Guerrero-Plata A, et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. 16(6), 1120-1128 (2008). (Pubitemid 351737078)
82. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother. 53(5), 2089-2099 (2009).
83. Enterlein S, Warfield KL, Swenson DL, et al. Vp35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50(3), 984-993 (2006). (Pubitemid 43327804)
84. Neuman BW, Stein DA, Kroeker AD, et al. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79(15), 9665-9676 (2005). (Pubitemid 41022309)
85. Neuman Bw, Stein Da, Kroeker Ad, et al. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78(11), 5891-5899 (2004).
86. Burrer R, Neuman BW, Ting JP, et al. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 81(11), 5637-5648 (2007). (Pubitemid 46847003)
87. Zhang YJ, Stein DA, Fan SM, et al. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Vet. Microbiol. 117(2-4), 117-129 (2006). (Pubitemid 44415350)
88. Vagnozzi A, Stein Da, Iversen Pl, Rieder E. Inhibition of foot-and-mouth disease virus infections in cell cultures with antisense morpholino oligomers. J. Virol. 81(21), 11669-11680 (2007). (Pubitemid 47623799)
89. Sleeman K, Stein DA, Tamin A, Reddish M, Iversen PL, Rota PA. Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res. 140(1-2), 49-56 (2009).
90. Ge Q, Pastey M, Kobasa D, et al. Inhibition of multiple subtypes of influenza a virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 50(11), 3724-3733 (2006). (Pubitemid 44684887)
91. Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD. Morpholino oligomers targeting the pb1 and np genes enhance the survival of mice infected with highly pathogenic influenza a H7N7 virus. J. Gen. Virol. 89, 939-948 (2008).
92. Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of influenza a H3N8 virus infections in mice by morpholino oligomers. Arch. Virol. 153(5), 929-937 (2008).
93. Stein DA. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr. Pharm. Des. 14(25), 2619-2634 (2008).
94. Zhang YJ, Wang KY, Stein DA, et al. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res. 73(1), 12-23 (2007). (Pubitemid 46080474)
95. Zhang YJ, Bonaparte RS, Patel D, Stein DA, Iversen PL. Blockade of viral interleukin-6 expression of kaposi's sarcoma-associated herpesvirus. Mol. Cancer Ther. 7(3), 712-720 (2008). (Pubitemid 351482154)
96. Moerdyk-Schauwecker M, Stein DA, Eide K, et al. Inhibition of hsv-1 ocular infection with morpholino oligomers targeting icp0 and icp27. Antiviral Res. 84(2), 131-141 (2009).
97. Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134(4), 577-586 (2008).
98. Van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide pro051. N. Engl. J. Med. 357(26), 2677-2686 (2007).
99. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12(2), 175-177 (2006). (Pubitemid 43214742)
100. Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther. 13(24), 1677-1685 (2006). (Pubitemid 44849032)
101. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient MDX mice. Hum. Mol. Genet. 18(22), 4405-4414 (2009).
102. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc. Res. 85(3), 444-453 (2010).